Waldencast plc WALD R2K
Company Overview
Waldencast plc operates in the beauty and wellness industry in the United States, Canada, Europe, the Middle East, India, Australia, and New Zealand. The company operates through two segments, Obagi Medical and Milk Makeup. It offers skin care products to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and protect and enhance skin tone and texture; cosmetics; and other beauty products. In addition, the company provides foundation, concealer, primer, blush, setting spray, and bronzer categories, as well as sells liner, eyeshadow, and lip color products. It serves distributors, retailers, physicians, and directly to consumers through its e-commerce platforms, and third-party logistics and delivery providers. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Why Investors Should Care
Revenue has grown at a 24.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.30.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $272.07M (-0.7% YoY); net profit $-229.75M.
- Trailing 12 Months Year-on-year growth — revenue -1.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 24.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 24.07% |
| 1 Year: | -1.70% |
Stock Price Performance
| 1 Year: | -27.86% |
| 6 Months: | -11.78% |
| 3 Months: | -19.48% |
| 1 Month: | -3.82% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 24.1% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 55.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | WALD Waldencast plc R2K | 1.38 | -0.72 | $163.17M | 0.00% | -9.67% | -40.33% | 24.07% | - |
| 2 | WMT Walmart Inc. SPXR3K | 107.14 | 37.73 | $852.63B | 0.88% | 16.83% | 24.13% | 3.82% | 3.24% |
| 3 | COST Costco Wholesale Corporation NDXSPXR3K | 915.74 | 46.16 | $406.11B | 0.62% | 25.96% | 29.15% | 8.16% | 11.45% |
| 4 | KO The Coca-Cola Company SPXR3K | 88.07 | 26.45 | $378.93B | 2.44% | 16.47% | 42.05% | 2.86% | 4.46% |
| 5 | PG The Procter & Gamble Company SPXR3K | 146.44 | 22.32 | $341.00B | 2.96% | 22.49% | 30.29% | 0.52% | 1.59% |
| 6 | PM Philip Morris International Inc. SPXR3K | 182.53 | 25.07 | $284.49B | 3.13% | 34.03% | -113.55% | -1.69% | 3.57% |
| 7 | PEP PepsiCo, Inc. NDXSPXR3K | 137.63 | 18.04 | $188.00B | 4.28% | 15.41% | 51.51% | 4.93% | 2.11% |
| 8 | BUD Anheuser-Busch InBev SA/NV | 80.35 | 17.32 | $140.40B | 1.61% | 8.49% | 11.39% | 0.88% | 4.63% |
| 9 | MO Altria Group, Inc. SPXR3K | 68.88 | 14.50 | $115.01B | 6.26% | 38.27% | - | 1.24% | -1.89% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 |
|---|---|---|---|---|
| Operating Income | -117.52K | -201.57K | -645.12K | -4.00M |
| Net Income | -1.18M | -1.55M | 7.76M | - |
| Diluted EPS | -0.13 | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 142.47M | 218.14M | 273.87M | 272.07M |
| Cost of Revenue | 55.04M | 76.56M | 82.12M | 89.05M |
| Gross Profit | 87.44M | 141.58M | 191.74M | 183.02M |
| Operating Expenses | 89.06M | 223.51M | 245.30M | 247.98M |
| Operating Income | -1.62M | -81.93M | -53.55M | -64.97M |
| EBITDA | 15.04M | -33.54M | 28.63M | -177.97M |
| Interest Expense | 11.12M | 18.91M | 17.16M | 25.09M |
| Pretax Income | -9.97M | -112.94M | -48.54M | -262.25M |
| Tax Provision | 9.60M | -6.97M | 110.00K | -14.19M |
| Net Income | -19.58M | -89.98M | -42.44M | -229.75M |
| Diluted EPS | -2.45 | -0.99 | -0.39 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 166.79K | - | 1.09B | 1.04B | 975.86M | 746.16M |
| Current Assets | - | - | 91.04M | 107.33M | 103.62M | 126.94M |
| Cash & Equivalents | - | - | 8.69M | 21.09M | 14.80M | 30.38M |
| Inventory | - | - | 54.38M | 55.68M | 53.10M | 54.61M |
| Receivables | - | - | 19.26M | 21.33M | 25.48M | 28.01M |
| Total Liabilities | 177.74K | - | 290.18M | 273.44M | 245.92M | 246.06M |
| Current Liabilities | 177.74K | - | 72.50M | 62.71M | 76.89M | 74.55M |
| Long Term Debt | - | - | 159.23M | 151.26M | 137.14M | 135.75M |
| Total Debt | - | - | 199.25M | 177.72M | 182.11M | 149.01M |
| Total Equity | -10.95K | - | 639.24M | 624.63M | 662.32M | 461.88M |
| Shares Outstanding | - | - | 107.56M | 122.08M | 122.69M | 128.24M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 3.53M | -29.77M | -8.82M | -12.82M |
| Investing Cash Flow | -3.79M | -1.99M | -2.92M | 76.23M |
| Financing Cash Flow | 5.16M | 44.33M | 5.58M | -47.22M |
| Capital Expenditure | -1.29M | -2.05M | -3.01M | -3.67M |
| Free Cash Flow | 2.24M | -31.82M | -11.83M | -16.48M |
| Net Change in Cash | 4.90M | 12.56M | -6.16M | 16.19M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 61.4% | 64.9% | 70.0% | 67.3% |
| Operating Margin % | -1.1% | -37.6% | -19.6% | -23.9% |
| Net Margin % | -13.7% | -41.2% | -15.5% | -84.4% |
| ROE % | - | -14.4% | -6.4% | -49.7% |
| ROCE % | - | -8.4% | -6.0% | -9.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Zeno Equity Partners LLP | 10.15% | 12.25M | $16.42M |
| 2 | Milestones Administradora De Recursos Ltda. | 2.01% | 2.43M | $3.25M |
| 3 | Stoic Point Capital Management LLC | 1.34% | 1.61M | $2.16M |
| 4 | Millennium Management Llc | 0.48% | 577.01K | $773.19K |
| 5 | Schonfeld Strategic Advisors Llc | 0.38% | 462.17K | $619.30K |
| 6 | Jane Street Group, LLC | 0.36% | 429.07K | $574.95K |
| 7 | Beartown Capital Management, LLC | 0.25% | 300.00K | $402.00K |
| 8 | AQR Capital Management, LLC | 0.23% | 272.43K | $365.05K |
| 9 | Qube Research & Technologies Ltd | 0.14% | 169.01K | $226.47K |
| 10 | Renaissance Technologies, LLC | 0.13% | 162.70K | $218.02K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for WALD
Obagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel
Approval Further Expands Obagi Medical’s Injectable Portfolio and Strengthens Its Position as a Leading Dermatological MegabrandLONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a globa…
Waldencast Announces Sale of Obagi Medical to Bridgepoint
LONDON, June 01, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics busines…
Obagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting
Data from the ALOHA Program and NU-GEN™ Cellular Renewal Serum Showcase Results to Help Drive Practice SuccessNEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic soluti…
Obagi and Next Health Partner to Launch “The Skin Recharge Station” Pop-Up Experience
A multi-city pop-up introducing consumers to the future of skincare and longevity innovation OBAGI NU-GEN Cellular Renewal Serum OBAGI NU-GEN Cellular Renewal Serum NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leade…
How Waldencast (WALD) Story Is Shifting As Targets Fall And Brand Hopes Persist
The fair value estimate for Waldencast has been reset from US$3.08 to US$1.87 per share, putting the recent round of reduced price targets into clear focus. This shift sits alongside research that separates analysts into those concerned abo…
Obagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin*
Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 delivers advanced mineral protection with skincare benefits for daily defense Obagi Sun Shield Obagi Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 NEW YORK, April 3…
WALD — Frequently Asked Questions
What is the current share price of Waldencast plc (WALD)?
As of 2026-09-07 16:24 PDT, Waldencast plc (WALD) trades at $1.38 on NasdaqCM. Its 52-week range is $0.76 to $3.08.
What is the market capitalisation of WALD?
Waldencast plc (WALD) has a market capitalisation of $163.17M on NasdaqCM.
What is the P/E ratio of WALD?
WALD trades at a trailing price-to-earnings (P/E) ratio of -0.72. The industry average P/E is 18.74. Its price-to-book (P/B) ratio is 0.36.
What is the return on equity (ROE) of WALD?
WALD has a return on equity (ROE) of -40.33%. Its return on capital employed (ROCE) is -9.67%.
Is WALD a good stock to buy?
This page provides a data-driven analysis of Waldencast plc (WALD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.